Acquired Company

Jade Biosciences completed its merger with Aerovate Therapeutics on April 28, 2025, with the combined company to trade on Nasdaq under the ticker JBIO.

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. It also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts. Show more

Location: Building 23, Waltham, MA, 02453, United States | Website: https://jadebiosciences.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

769.8M

52 Wk Range

$6.57 - $100.10

Previous Close

$15.61

Open

$15.62

Volume

1,820

Day Range

$15.62 - $15.62

Enterprise Value

560.3M

Cash

198.9M

Avg Qtr Burn

-11.31M

Insider Ownership

0.99%

Institutional Own.

80.23%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
JADE101 Details Immunoglobulin A nephropathy (IgAN)	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
JADE201 Details Rheumatoid arthritis	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.